WisdomTree BioRevolution Fund
$23.27−0.63 (−2.64%)
- Expense ratio
- 0.45%
- Fund size
- $5M
- 1Y return
- +63.7%
- Yield · Last 12 months
- 3.22%
- Holdings
- 99
- Volume · 30D
- 0M sh
- NAV per share
- $23.10
- 52W range
The ETF.net WDNA Grade
Score 40 of 100 sits in the C band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E. A structural cap ceilings this fund at 40, so B and A are out of reach.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.BScore 56Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.BScore 67Category rankRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.CScore 40Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.FScore 6Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.AScore 73Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.FScore 20Category rank
Our read on WDNA
CMost biotech funds stop at drug developers. WDNA follows biology out of the clinic and into food, materials and industrial chemistry, tracking a WisdomTree index shaped with futurist Jamie Metzl.
The Fund seeks to track the WisdomTree BioRevolution Index before fees and expenses. It uses a passive representative-sampling approach to gain global equity exposure to companies expected to be significantly transformed by advances in genetics and biotechnology.
Why people hold it
- Wider map than a pipeline fund: the index sorts companies across human health, agriculture and food, materials/chemicals/energy, and biological machines and interfaces.wisdomtree.com
- The 0.45% expense ratio sits under the median for genomics and biotech thematics, which is unusual for a niche with this much research behind the index.
- Passive and global by design: roughly 100 listed names worldwide, sampled to track the WisdomTree BioRevolution Index rather than picked by a manager.wisdomtree.com
Worth knowing
- A small, thinly traded fund. Spreads can run wider than the category heavyweights, so the price you get may drift from the value of what you own.
- For plain biotech exposure, bigger peers cost less: IBBQ at 0.19% and XBI at 0.35%. You pay WDNA's fee for the broader multi-sector definition.
- The issuer flags the theme's own hazards: intense competition, fast product obsolescence, intellectual-property loss, and shifting government rules.wisdomtree.com
WDNA Holdings
- Stocks
- 99
- 39%
- TWST
Sectors
- Health Care90.1%
- Materials6.1%
- Cons. Staples3.9%
Geography
- United States85.04%
- United Kingdom4.07%
- Germany2.93%
- Switzerland2.66%
- Netherlands2.22%
- Denmark1.84%
- Belgium0.68%
- Australia0.56%
WDNA Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | WDNA |
|---|---|
| Year to date | +41.6% |
| 1 month | +1.0% |
| 3 months | +25.6% |
| 1 year | +63.7% |
| 3 years | +18.5% |
| 5 years | −0.9% |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | WDNA |
|---|---|---|
| 2026 YTD | +41.6% | |
| 2025 | +22.7% | |
| 2024 | −14.1% | |
| 2023 | −2.1% | |
| 2022 | −26.3% | |
| 2021 | −5.3% |
WDNA in the news
ETF.net Research hasn’t filed on WDNA yet — coverage lands here as it’s written.
WDNA Dividends
- 3.22%
- $0.77
- $0.77 per share
- Annual
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Dec 26, 2025 | Dec 30, 2025 | $0.77 |
| Dec 26, 2024 | Dec 30, 2024 | $0.11 |
| Dec 22, 2023 | Dec 28, 2023 | $0.14 |
| Dec 23, 2022 | Dec 29, 2022 | $0.07 |
| Dec 27, 2021 | Dec 30, 2021 | $0.02 |
WDNA Risk
- 26.1%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.45
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −57.7%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 1.26
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
WDNA Cost
- The middle half of Biotech & Genomics funds
- Median 0.47%
5 of the 15 Biotech & Genomics funds charge less.